Simon Quick Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-10,918
Closed -$758K 552
2025
Q1
$758K Buy
10,918
+4,241
+64% +$350K 0.04% 208
2024
Q4
$574K Sell
6,677
-22
-0.3% -$2.38K 0.03% 222
2024
Q3
$798K Buy
6,699
+832
+14% +$111K 0.05% 184
2024
Q2
$837K Buy
5,867
+570
+11% +$75.5K 0.06% 149
2024
Q1
$680K Buy
5,297
+2,168
+69% +$258K 0.05% 159
2023
Q4
$324K Sell
3,129
-973
-24% -$96.2K 0.03% 229
2023
Q3
$373K Buy
4,102
+224
+6% +$19.7K 0.04% 201
2023
Q2
$314K Buy
3,878
+130
+3% +$10.6K 0.03% 200
2023
Q1
$298K Buy
+3,748
New +$266K 0.03% 213
2020
Q4
Sell
-814
Closed -$28K 514
2020
Q3
$28K Buy
+814
New +$27.1K 0.01% 277
2020
Q1
Sell
-1,850
Closed -$54K 637
2019
Q4
$54K Buy
1,850
+1,632
+749% +$45.2K 0.02% 213
2019
Q3
$6K Buy
218
+118
+118% +$2.98K ﹤0.01% 288
2019
Q2
$2.55K Buy
+100
New +$2.47K ﹤0.01% 344
2018
Q4
Sell
-234
Closed -$6K 356
2018
Q3
$6K Hold
234
﹤0.01% 253
2018
Q2
$5K Hold
234
﹤0.01% 292
2018
Q1
$6K Hold
234
﹤0.01% 254
2017
Q4
$6K Buy
+234
New +$5.95K ﹤0.01% 356
2017
Q1
Sell
-33,990
Closed -$609K 369
2016
Q4
$609K Buy
+33,990
New +$616K 0.45% 46

Other funds holding NVO

Simon Quick Advisors's NVO Position: Q2 2025 in Review

Simon Quick Advisors sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 10,918 shares — an estimated $758K sold.

Simon Quick Advisors first reported a position in NVO in Q4 2016 and held it in 18 quarters. The position peaked at $837K in Q2 2024. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Simon Quick Advisors reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Simon Quick Advisors sold 10,918 Novo Nordisk shares in Q2 2025, an estimated $758K.
  • Simon Quick Advisors first reported a position in Novo Nordisk in Q4 2016 and held it in 18 quarters.
  • Simon Quick Advisors's Novo Nordisk position peaked at $837K in Q2 2024.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Simon Quick Advisors's 13F filing for Q2 2025, filed 4 Aug 2025.